A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Inclusion Criteria: * HIV-1 infected females (gender at birth) \>=18 years of age * Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol) * HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=500 c/mL. * Documentation that the subject is negative for the HLA-B\*5701 allele. * Antiretroviral-naïve (\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection). * Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening. Exclusion Criteria: * Women who are pregnant or breastfeeding * Women who plan to become pregnant during the first 48 weeks of the study * Any subject who has had a medical intervention for gender reassignment * Any evidence of an active Centers for Disease Control and Prevention (CDC) Category C disease * Subjects with any degree of hepatic impairment * Subjects positive for hepatitis B at Screening, or anticipated need for HCV therapy during the study * History or presence of allergy to the study drugs or their components or drugs of their class * Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia * poses a significant suicidality risk * History of osteoporosis with fracture or requiring pharmacologic therapy * Treatment with an HIV-1 immunotherapeutic …